Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

India's Union Health Ministry has been asked to examine concerns over the safety and quality of coronary stents.

This comes after three models of drug-eluting stents (DES) made by India-based medical device company, Meril Life Sciences Pvt. Ltd, were reportedly withdrawn in Sri Lanka over quality issues.

India-Made Coronary Stent Under Scrutiny

Sri Lanka drug regulatory body, National Medicines Regulatory Authority (NMRA), reportedly issued the instructions for withdrawal of these stents in June 2026. The Cabinet Secretariat urged the Health Ministry to look into the concerns on October 5, after a representation by Rajya Sabha member Ajeet Madhav Gopchade who is also a medical doctor.

According to Sri Lanka Mirror, the concerns include improper stent positioning, stent dislodgement, acute stent thrombosis, and failure of the devices to expand adequately after implantation.

Stent thrombosis occurs when a blood clot forms inside the implanted stent, potentially blocking blood flow to the heart. Acute stent thrombosis is particularly serious because it can lead to a heart attack and requires urgent medical attention.

These complications can affect the success of a procedure and may put patients' lives at risk.

These issues were identified after an investigation was conducted by the Medical Device Evaluation Committee (MDEC) of the NMRA. The regulatory body also said that these defects necessitate the use of supplementary devices, which resulted in wastage of precious time and unnecessary added expenses.

In his representation, Gopchade addresses the media reports about the withdrawal of three stent models in Sri Lanka.

Need For Better Monitoring After Stent Implantation

Also read: Mammogram May Spot Hidden Heart Risk That Doctors Miss In Women

Gopchade urged the government to assess whether India's regulatory system needs further strengthening to address risks that come after coronary stent implantation.

In his letter dated October 5, he said the reported developments required closer scrutiny to protect patients. “These reports highlight that Indian-patient-safety issues that India needs to examine carefully and address proactively,” he said in the representation, according to The Economic Times.

He called for rigorous device testing, clinical decision-making, and monitoring of complications after stent implantation. He said that safety checks should not end once a medical device has received regulatory approval.

Gopchade called for better documentation to ensure that stents are used only when medically indicated, and that alternative treatments are considered first.

He also proposed stronger monitoring of the performance of medical devices after they enter routine clinical use. Such monitoring can help spot complications that may not have been apparent during initial testing.

Gopchade further urged the government to establish a mechanism for reviewing safety alerts, recalls and withdrawals issued by foreign regulators effectively.

This would help authorities assess whether a device flagged overseas is also being marketed or used in India and whether investigation is needed.

What Are Coronary Stents?

Coronary stents are small, mesh-like tubes that are placed inside narrowed or blocked coronary arteries to help restore blood flow to the heart. They are used during angioplasty, a procedure that opens blocked arteries in people with coronary artery disease.

Drug-eluting stents release medication over time to reduce the risk of the artery narrowing again. While these devices can help restore blood flow and improve cardiovascular health, their safety depends on their quality, correct placement, and post-procedure care.

People who have had COVID-19 may be more likely to need allergy medications months after initial infection, according to a large Japanese study.

The study analysed health records of more than 778,000 people, suggesting that the effects of COVID-19 may extend beyond the respiratory illness and could be related to immune function after infection.

The study, published in BMC Public Health, examined whether people diagnosed with COVID-19 were more likely to receive new prescriptions for allergy medications than individuals who had not contracted the infection.

Researchers analysed health insurance records for 778,362 people diagnosed with COVID-19 and compared them to a group of individuals who were not infected.

They tracked new prescriptions for four categories of allergy medications, including antihistamines, leukotriene receptor antagonists, eye drops for allergic conditions and nasal sprays used to treat rhinitis.

Over a median follow-up period of seven months, people who had COVID-19 were 21% more likely to receive a new prescription for allergy medication than those in the comparison group.

The association was stronger among older adults and people with pre-existing health conditions. The researchers also found that elevated prescription rates remained detectable beyond one year after infection in a few high-risk groups.

However, the study merely identifies an association between infection and subsequent use of allergy medications and does not establish a causal link.

How Could COVID-19 Affect Allergy Risk?

Also read: XFG Variant In Spain: COVID-19 Cases Rise Amid Respiratory Infection Surge

Allergies occur when the immune system overreacts to substances that are usually harmless, like pollen, dust mites or certain foods. This response can trigger symptoms including sneezing, itching, a runny nose, skin rashes and watery eyes.

Antihistamines work by blocking the effects of histamine, a chemical that is released during these allergic reactions. Leukotriene receptor antagonists target inflammatory elements involved in conditions like asthma and allergic rhinitis.

Researchers believe that infections caused by respiratory viruses can sometimes alter immune responses, affecting processes involved in allergic inflammation.

COVID-19 has been known to cause changes in immune system that can last beyond the initial illness. Damage to the lining of the respiratory tract and changes in inflammatory response could influence how the body responds to allergens.

However, these mechanisms were not directly established by the Japanese study. The researchers used prescription records rather than laboratory tests to confirm newly developed allergic diseases.

Who Is At Greater Risk?

Also read: Long COVID: Mouth And Lung Bacteria May Offer Clues

The association between COVID-19 and new allergy medication prescriptions was more pronounced among people aged 65 and older.

In this group, the rate of new prescriptions was 33% higher among those who had contracted COVID-19 than among their matched counterparts. Among people with substantial pre-existing illnesses, the rate was 35% higher.

The researchers also found that it lasted more than one year in these groups, although it gradually weakened over time.

These findings suggest that older adults and people managing multiple health conditions may warrant closer attention to new symptoms following COVID-19.

The study's large sample size provides useful evidence about patterns in allergy medication use after COVID-19. But a prescription does not always mean a new allergy diagnosis. Some medications included in the analysis can be prescribed for conditions other than allergies, and people recovering from COVID-19 may have more opportunities to consult doctors or receive prescriptions.

The findings also come from Japan and may not apply equally to populations with different healthcare systems, demographics or patterns of medication use. Further research is needed to determine whether COVID-19 contributes to the development of new allergic conditions.

Pope Leo XIV recently underwent lung cancer surgery to have the lower lobe of his right lung removed. According to the Vatican, the 71-year-old pontiff's recovery is on track. But doctors are awaiting further test results to determine whether he needs further treatment. The pope has resumed eating, walking and celebrating Mass but he is not fit to take a trip just yet.

The pope underwent surgery at Rome's Gemelli Hospital on October 13 after doctors identified a suspicious lung nodule. The procedure confirmed lung adenocarcinoma, the most common type of lung cancer, and surgeons removed the lower lobe of his right lung.

In a update on October 14, the pope's personal physician, Dr Luigi Carbone, and thoracic surgeon Professor Stefano Margaritora said, "The Holy Father underwent respiratory physiotherapy and has begun walking in his room. He resumed his regular diet and had breakfast and lunch." They added, "Recovery is proceeding as planned."

Blood tests and a chest X-ray indicated that the pope was recovering normally after the operation. He also celebrated Mass with his secretaries in a private hospital chapel.

However, doctors have not yet disclosed whether the cancer has spread to the lymph nodes or other parts of the body. That will help determine if further treatment is needed.

Talking about who is at the highest risk of developing lung adenocarcinoma, Dr. AVS Suresh - Sr. Consultant, Medical Oncology, American Oncology Institute, Hyderabad, told HealthandMe, "Lung adenocarcinoma is the most common subtype of lung cancer. Smoking remains one of the strongest risk factors, but this cancer can also develop in people who have never smoked."

He added, "People at higher risk include current and former smokers, those exposed to second-hand smoke, people exposed to radon, asbestos or certain workplace pollutants, and individuals with a family history of lung cancer. Risk also generally increases with age. Importantly, not smoking does not eliminate the risk: lung adenocarcinoma is a recognised cause of lung cancer among never-smokers as well."

Surgery For Lung Lobe

The lungs are divided into sections called lobes. The right lung has three lobes, while the left lung has two. When cancer is confined to a particular area, surgeons may remove the affected lobe in an operation called a lobectomy.

The procedure aims to remove the tumour along with surrounding tissue to reduce the likelihood of cancer remaining in the lung. Nearby lymph nodes may also be removed and examined to check whether cancer cells have spread.

Pope Leo underwent surgery assisted by video, a minimally invasive technique that uses a camera and small surgical incisions to operate inside the chest.

Dr PierCarlo Gentile, head of radiation oncology at Rome's San Pietro Fatebenefratelli Hospital, told The Associated Press that this type of surgery typically requires around 15 to 20 days of recovery. He also said that in this case postoperative complications, including infections, is rare.

Also read: Pope Leo XIV, Diagnosed With Lung Cancer, Undergoes Surgery As His Brother Battles Relapsed Multiple Myeloma

Recovery After Lung Lobe Removal

After a lobectomy, the remaining lung tissue can help compensate for some of the lost lung capacity. However, recovery varies depending on a person's age, overall health, lung function before surgery and the extent of the operation.

Dr. Suresh explained, "Recovery generally takes several weeks to a few months, depending on the surgical approach, age, overall health and any complications. Patients may initially experience pain, fatigue, coughing or breathlessness. Removing a lung lobe reduces the amount of lung tissue available for breathing, so some reduction in lung function is expected.

The oncologist further explained that it does not necessarily mean a person will have lasting, disabling breathlessness. The remaining lung tissue can adapt, and many patients return to their usual daily activities. The extent of any long-term change depends on their lung function before surgery and how well recovery progresses.

Additionally, in the initial days, patients are encouraged to get out of bed and walk as soon as medically appropriate. Movement after surgery helps reduce the risk of blood clots and other complications linked with bed rest and inactivity.

Respiratory physiotherapy is also a part of recovery. Breathing exercises help patients expand their remaining lung tissue, improve ventilation and clear secretions from the airways. Some patients may also need oxygen support temporarily.

Pain management, proper nutrition and slow and gradual increases in physical activity are important. Breathlessness and fatigue can persist for weeks, and full recovery may take longer than the initial hospital stay.

Also read: Pope Leo XIV’s Lung Cancer Diagnosis: When Should You Worry About Lung Nodules?

Additional Cancer Treatment

The need for additional treatment for Pope Leo will depend on the final results, including the tumour's size and other factors.

Dr. Suresh said, "Lung adenocarcinoma can recur even after surgery has removed the visible tumour. The likelihood depends mainly on the cancer’s stage, tumour size and biological characteristics, whether cancer cells were found in the lymph nodes, and whether the surgical margins are clear."

If the cancer is localised and has been completely removed, surgery may be sufficient in some cases. If tests show that the disease has spread or carries features associated with a higher risk of recurrence, doctors may consider chemotherapy, immunotherapy or targeted therapy, depending on the tumour's characteristics.

The doctor further explained, "For patients whose cancer is detected early and completely removed, the outlook is generally more favourable. If the cancer has spread to lymph nodes or beyond the lung, the risk of recurrence is higher, and additional treatment may be recommended to reduce that risk. No surgery can guarantee that cancer will never return, because microscopic cancer cells may sometimes remain undetected."

Long-term follow-up is therefore important, usually involving scheduled consultations and chest imaging such as CT scans. For Pope Leo, it would be premature to give a reliable individual recurrence percentage without his final stage and pathology findings.